LXRX (Lexicon Pharmaceuticals, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by LXRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-04 | CHRISTOPHER J SOBECKI | Director | M | — | — |
| 2026-06-04 | Ivan Cheung | Director | M | — | — |
| 2026-06-04 | RAYMOND DEBBANE | Director | M | — | — |
| 2026-06-04 | Philippe Amouyal | Director | M | — | — |
| 2026-06-04 | Judith L Swain | Director | M | — | — |
| 2026-06-04 | Diane E. Sullivan | Director | M | — | — |
| 2026-06-04 | SAM L BARKER | Director | M | — | — |
| 2026-05-08 | International S.C.A. Artal | Director | M | — | — |
| 2026-05-04 | Ivan Cheung | Director | A | — | — |
| 2026-05-04 | SAM L BARKER | Director | A | — | — |
| 2026-05-04 | Philippe Amouyal | Director | A | — | — |
| 2026-05-04 | RAYMOND DEBBANE | Director | A | — | — |
| 2026-05-04 | CHRISTOPHER J SOBECKI | Director | A | — | — |
| 2026-05-04 | Judith L Swain | Director | A | — | — |
| 2026-05-04 | Diane E. Sullivan | Director | A | — | — |
| 2026-03-03 | Michael Exton | Chief Executive Officer | MIXED | — | — |
| 2026-03-03 | Rachel Yap Martens | SVP, Partnerships & Corp Strat | MIXED | — | — |
| 2026-03-03 | Lisa DeFrancesco | SVP, IR and Corp Comm | MIXED | — | — |
| 2026-03-03 | Craig B Granowitz | SVP, Chief Medical Officer | MIXED | — | — |
| 2026-03-03 | Brian T Crum | SVP, General Counsel & Secr. | MIXED | — | — |
| 2026-03-03 | Wendy McDermott | SVP, Human Resources | MIXED | — | — |
| 2026-03-03 | Suma Gopinathan | SVP, Discovery | MIXED | — | — |
| 2026-03-03 | Scott M Coiante | SVP, Chief Financial Officer | MIXED | — | — |
| 2026-02-27 | RAYMOND DEBBANE | Director | Buy | — | — |
| 2026-02-25 | RAYMOND DEBBANE | Director | Buy | — | — |
| 2026-02-23 | RAYMOND DEBBANE | Director | Buy | — | — |
| 2026-02-19 | Artal Group S.A. | Director | A | — | — |
| 2026-02-18 | RAYMOND DEBBANE | Director | Buy | — | — |
| 2026-02-17 | Scott M Coiante | SVP, Chief Financial Officer | A | — | — |
| 2026-02-17 | Craig B Granowitz | SVP, Chief Medical Officer | A | — | — |
| 2026-02-17 | Michael Exton | Chief Executive Officer | A | — | — |
| 2026-02-17 | Wendy McDermott | SVP, Human Resources | A | — | — |
| 2026-02-17 | Lisa DeFrancesco | SVP, IR and Corp Comm | A | — | — |
| 2026-02-17 | Suma Gopinathan | SVP, Discovery | A | — | — |
| 2026-02-17 | Rachel Yap Martens | SVP, Partnerships & Corp Strat | A | — | — |
| 2026-02-17 | Brian T Crum | SVP, General Counsel & Secr. | A | — | — |
| 2026-02-04 | Artal Group S.A. | Director | MIXED | — | — |
| 2025-06-03 | Diane E. Sullivan | Director | A | — | — |
| 2025-06-03 | Ivan Cheung | Director | A | — | — |
| 2025-06-03 | CHRISTOPHER J SOBECKI | Director | A | — | — |
| 2025-06-03 | RAYMOND DEBBANE | Director | A | — | — |
| 2025-06-03 | SAM L BARKER | Director | A | — | — |
| 2025-06-03 | Judith L Swain | Director | A | — | — |
| 2025-06-03 | Philippe Amouyal | Director | A | — | — |
| 2025-05-13 | SAM L BARKER | Director | M | — | — |
| 2025-05-13 | CHRISTOPHER J SOBECKI | Director | M | — | — |
| 2025-05-13 | Philippe Amouyal | Director | M | — | — |
| 2025-05-13 | Diane E. Sullivan | Director | M | — | — |
| 2025-05-13 | Judith L Swain | Director | M | — | — |
| 2025-05-13 | RAYMOND DEBBANE | Director | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 175,156,062 | — |
| — | Director | 136,180,481 | — |
| — | Director | 40,450,678 | — |
| — | Director | 35,402,689 | — |
| — | Director | 21,321,961 | — |
| — | Director | 5,782,749 | — |
| — | Director | 4,304,741 | — |
| — | Director | 3,533,960 | — |
| — | Director | 3,516,214 | — |
| — | Director | 3,006,678 | — |
| — | Director | 2,130,717 | — |
| — | Chief Executive Officer | 1,159,439 | — |
| — | Director | 1,150,922 | — |
| — | Chief Executive Officer | 503,263 | — |
| — | SVP, General Counsel & Secr. | 428,802 | — |
| — | Director | 408,434 | — |
| — | Director | 374,486 | — |
| — | President and COO | 312,792 | — |
| — | Director | 293,177 | — |
| — | EVP, Innov & Chem Sciences | 281,391 | — |
| — | President & CEO | 261,946 | — |
| — | Director | 218,771 | — |
| — | SVP, Human Resources | 201,659 | — |
| — | Director | 174,486 | — |
| — | SVP, Chief Financial Officer | 160,237 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LXRX quote page; the site-wide leaderboard is on the insider transactions hub.